These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26924035)

  • 21. [Modern times: back to past, back to future].
    Feliu J; Zabalza A; García-Muñoz R; Olavarría E
    Med Clin (Barc); 2012 Jul; 139(4):180-1. PubMed ID: 22281094
    [No Abstract]   [Full Text] [Related]  

  • 22. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
    Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can FCR be curative in CLL?
    Killock D
    Nat Rev Clin Oncol; 2015 Dec; 12(12):684. PubMed ID: 26573420
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
    Nakazawa H; Nishina S; Mimura Y; Kawakami T; Senoo Y; Sakai K; Nakazawa K; Kitano K
    Int J Hematol; 2014 Jun; 99(6):782-5. PubMed ID: 24584911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Mar; 140(3):246-7. PubMed ID: 23466166
    [No Abstract]   [Full Text] [Related]  

  • 26. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
    Nabhan C
    Clin Cancer Res; 2008 Jul; 14(13):4353. PubMed ID: 18594019
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
    Assouline S; Buccheri V; Delmer A; Gaidano G; McIntyre C; Brewster M; Catalani O; Hourcade-Potelleret F; Sayyed P; Badoux X
    Br J Clin Pharmacol; 2015 Nov; 80(5):1001-9. PubMed ID: 25900065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical challenges in chronic lymphocytic leukemia.
    O'Brien S
    Semin Hematol; 1998 Jul; 35(3 Suppl 3):22-6. PubMed ID: 9685176
    [No Abstract]   [Full Text] [Related]  

  • 30. Exacerbation of lymphomatoid papulosis during rituximab therapy.
    McCurdy O; McCormack C; Ritchie D; Prince HM
    Australas J Dermatol; 2014 Feb; 55(1):e1-3. PubMed ID: 23190403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
    J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and therapeutic challenges.
    Ascaso FJ; Jimenez B; Fuertes MA; Sadda S; Keane PA
    Retina; 2011 May; 31(5):994-7. PubMed ID: 21102365
    [No Abstract]   [Full Text] [Related]  

  • 35. Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
    Garratty G; Petz LD
    Br J Haematol; 2007 Nov; 139(4):622-3. PubMed ID: 17979948
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
    Hanamura A; Hayakawa M; Naito K
    Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszyńska A; Roliński J
    Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
    [No Abstract]   [Full Text] [Related]  

  • 38. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
    Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL
    Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FCR holds up to the test of time: CLL8 follow-up.
    Woyach JA
    Blood; 2016 Jan; 127(2):172-3. PubMed ID: 26769769
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
    Brown JR
    Oncology (Williston Park); 2015 Jun; 29(6):442, 444. PubMed ID: 26091679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.